A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)Krish Patel, Gilles Salles, Laurie H. Sehn et al.|Blood|2025Cited by 0